A Novel and Fast Purification Method for Nucleoside Transporters

Zhenyu Hao1,2†, Maren Thomsen2†, Vincent L. G. Postis2,3, Amelia Lesiuk2, David Sharples2, Yingying Wang1, Mark Bartlam2,4,5* and Adrian Goldman2,4,6*

1 Key Laboratory of Pollution Processes and Environmental Criteria, Ministry of Education, College of Environmental Science and Engineering, Nankai University, Tianjin, China, 2 Faculty of Biological Sciences, Astbury Centre for Structural Molecular Biology, School of Biomedical Sciences, University of Leeds, Leeds, UK, 3 Biomedicine Research Group, Faculty of Health and Social Sciences, Leeds Beckett University, Leeds, UK, 4 Department of Molecular Biology and Biochemistry, College of Life Sciences, Nankai University, Tianjin, China, 5 State Key Laboratory of Medicinal Chemical Biology, Nankai University, Tianjin, China, 6 Division of Biochemistry, Department of Biosciences, University of Helsinki, Helsinki, Finland

Nucleoside transporters (NTs) play critical biological roles in humans, and to understand the molecular mechanism of nucleoside transport requires high-resolution structural information. However, the main bottleneck for structural analysis of NTs is the production of pure, stable, and high quality native protein for crystallization trials. Here we report a novel membrane protein expression and purification strategy, including construction of a high-yield membrane protein expression vector, and a new and fast purification protocol for NTs. The advantages of this strategy are the improved time efficiency, leading to high quality, active, stable membrane proteins, and the efficient use of reagents and consumables. Our strategy might serve as a useful point of reference for investigating NTs and other membrane proteins by clarifying the technical points of vector construction and improvements of membrane protein expression and purification.

Keywords: nucleoside transporters, membrane protein, vector construction, purification, expression

INTRODUCTION

Membrane proteins represent 20–30% of all genes in most sequenced genomes (Krogh et al., 2001) and are targets for about half of all modern therapeutic drugs (Krogh et al., 2001; Bayley, 2009; Andreeva et al., 2014). Membrane proteins, such as membrane transporters, receptors, enzymes, and cell adhesion molecules, have been studied for decades on account of their critical biochemical roles in the maintenance of vital cellular functions (Bowie, 2005; Von Heijne, 2006; Almén et al., 2009; Anson, 2009). However, production of native membrane proteins has always proven to be a bottleneck in structural and functional studies (Lacapere et al., 2007; Midgett and Madden, 2007). Current production methods generally lead to a low yield of expression or result in overexpression of misfolded protein (Drew et al., 2008).

Our particular interest is in nucleoside transporters (NTs). Their study is biologically and clinically relevant because they are important in the uptake of nucleoside drug analogs. Furthermore, nucleosides, adenosine in particular, regulate many aspects of heart, brain, and immune system physiology (Johnson et al., 2012; Young et al., 2013; Rehan and Jaakola, 2015) and so have great potential for therapeutic applications in cardiovascular disease, inflammation, and cancer (Carrier et al., 2006; Hsu et al., 2012; Young et al., 2013; Valdès et al., 2014). However, the molecular basis of the functional mechanisms of nucleoside transport remain poorly defined.
One of the main reasons lies in the difficulty of production and purification of recombinant NTs.

A standard approach for membrane protein production is the expression of the target membrane protein as a fusion protein, which can increase the stability and expression level of the target (Alexandrov et al., 2001; Heijbel et al., 2009) and/or makes it easier to follow the expression and purification (Drew et al., 2005). A diverse range of soluble proteins have been used as fusion partners including maltose binding protein (MBP), thioredoxin, green fluorescence protein (GFP), and glutathione S-transferase (GST) (Heijbel et al., 2009; Sammons and Gross, 2013; Gosch et al., 2014; Nguyen et al., 2014; Satoh et al., 2015). MBP is one of the most commonly used for the generation of fusion protein with membrane proteins in microbial expression systems (Lorenzo et al., 1997; Dälken et al., 2010; Xu et al., 2014). Because it is known to be well expressed and stable in the Escherichia coli periplasm, MBP is generally used as an N-terminal fusion of membrane proteins to be purified (Hu et al., 2011), but is not used as a purification tag because of the maltoside detergents used in solubilisation interfere. The inconvenience of using a His-tag directly as an N-terminal fusion of a membrane protein exposing its N-terminus in the periplasm is that the presence of the His positive tag can alter the protein topology (Von Heijne, 2006). To avoid this problem, we have used MBP as a linker between the purification tag (8xHis) and the membrane protein of interest, hence keeping the topological stability of the target as well as the flexibility of His-tag purification procedures (Ma et al., 2015). In addition, a specific proteolytic cleavage site is added between the MBP and the target protein. Classical approaches use proteases in solution together with the protein so, after cleavage, an additional step is needed to repurify the target protein from the protease and the cut tag. The approach we have undertaken in this study is to combine the use of a His tagged protease added directly onto the protein bound to the purification column. As a result, the target protein is specifically released into the flowthrough while the His-protease and the His-MBP are retained on the IMAC (immobilized metal-affinity chromatography) column, hence avoiding another round of purification. We have used NupC (Escherichia coli, Uniprot accession no.: POAFF2) as a model protein to demonstrate the efficiency of this approach, while additionally optimizing and simplifying each prior purification step to decrease purification time. This optimized purification procedure has been successfully applied to other NTs (SI-Figure 1). In addition, we developed an improved expression system by changing the promoter and the linker described in our earlier study (Ma et al., 2015). Compared to our previous approach, the optimized method is faster and more cost effective. Similar optimization approaches can be generally applied to the production of other membrane proteins.

Abbreviations: C12E8, octaethylene glycol monododecyl ether; DDM, dodecyl-β-D-maltoside; DM, decyl-β-D-maltoside; GFP, green fluorescence protein; GST, glutathione S-transferase; IMAC, immobilized metal-affinity chromatography; IPTG, isopropyl β-D-1-thiogalactopyranoside; LDAO, lauryldimethylamine-N-oxide (LDAO), and octaethylene glycol monododecyl ether (C12E8) were from Anacatre (Maumee, USA) and octyl β-D-glucopyranoside (OG) was from AFFYMETRIX Inc (Santa Clara, USA). Isopropyl β-D-thiogalactopyranoside (IPTG) was from Melford Ltd. (Chelsworth, UK). The vectors pL53 and pL55 employed in this study are as described in our previous report (Ma et al., 2015), and the same strategy was used to generate pL54.

MATERIALS AND METHODS

Reagents and Plasmids

We produced HRV-3C protease with an N-terminal octahistidine tag, which had been ligated into a pET28 derivative vector. The protease was purified by IMAC after expression in E. coli (Postis, unpublished). The detergents dodecyl-β-D-maltoside (DDM) and decyl-β-D-maltoside (DM) were from GLYCON Biochemicals GmbH (Luckenwalde, Germany), lauryldimethylamine-N-oxide (LDAO), and octaethylene glycol monododecyl ether (C12E8) were from Anacatre (Maumee, USA) and octyl β-D-glucopyranoside (OG) was from Affymetrix Inc (Santa Clara, USA). Isopropyl β-D-thiogalactopyranoside (IPTG) was from Melford Ltd. (Chelsworth, UK). The vectors pL53 and pL55 employed in this study are as described in our previous report (Ma et al., 2015), and the same strategy was used to generate pL54.

Protein Expression

The optimal expression conditions of proteins with the different vectors were obtained from expression optimizations following protocols in (Baldwin, 2000). A single colony was transferred in 300 ml Luria Broth medium for incubation overnight at 37°C. The large scale expression of the target protein was conducted in 30 l fermentor (Infors HT). The cells were grown in Terrific Broth medium at 37°C until an OD600 of 0.6 was reached. The expression of the target of interest was induced by the addition of 0.5 mM IPTG. The cells were harvested after 6 h by centrifugation.

Membrane Preparation

Membrane preparation was performed as previously published (Ma et al., 2015). Briefly, after being resuspended at 6 mg/ml (wet cell weight) in phosphate-buffered saline (PBS), the cells were disrupted at 30 kpsi using a TS series cell disruptor (Constant Systems Ltd., UK). The cell debris were removed by centrifugation at 14,000 g for 45 min. The membrane fraction was pelleted by ultracentrifugation at 100,000 g for 2 h. The membrane pellet was washed twice with PBS buffer. The final membrane pellet was resuspended in PBS buffer to a concentration of total membrane protein between 20 and 40 mg/ml and snap-frozen in liquid nitrogen.

Solubilisation Trials

Solubilisation trials were carried out using a final membrane protein concentration of 5 mg/ml in solubilisation buffer (Table 1) and 1% (w/v) of the tested detergents. Five different detergents were tested: DDM, DM, LDAO, C12E8, and OG. The resuspended samples were gently mixed for 2 h at 4°C. The suspensions were centrifuged at 100,000 g for 1 h. The protein of interest in the collected supernatants was detected by western blot (anti-histidine tag antibody) and its amount compared to the total amount of NupC present before centrifugation.

Protein Purification

All experiments were performed at 4°C unless stated otherwise. The standard purification was described in Ma et al. (2015) and the optimized purification was carried out as follow. Membrane
| Buffer                  | Composition                                                                 |
|------------------------|-----------------------------------------------------------------------------|
| 1×PBS                  | 10 mM Na₂HPO₄, 1.8 mM KH₂PO₄, 137 mM sodium chloride, 4 mM potassium chloride, pH 7.4 |
| Solubilisation buffer  | 50 mM Tris pH 7.4, 150 mM sodium chloride, 5% (w/v) glycerol, 5 mM imidazole |
| Purification buffer    | 50 mM potassium phosphate buffer pH 7.4, 150 mM sodium chloride, 5 mM imidazole, 5% glycerol (w/v), and 1% DDM |
| Wash buffer            | 50 mM potassium phosphate buffer pH 7.4, 150 mM sodium chloride, 15 mM imidazole, 0.05% DDM, and 10% glycerol (w/v) |
| Cleavage buffer        | 50 mM potassium phosphate buffer pH 7.4, 150 mM sodium chloride, 5% glycerol (w/v), and 0.05% DDM |

proteins (100 mg) were solubilised in purification buffer for 1 h. The non-solubilised material was removed by centrifugation (100,000 g for 1 h). The supernatant was collected and incubated with 4 ml HisPur™ Cobalt resin (Thermo Scientific™) for 1 h on a roller mixer. The resin was then packed into a column and washed with 10 column volumes (CV) of wash buffer. The washed resin was then resuspended in 1 CV of cleavage buffer and incubated for 2 h with the appropriate amount of HRV-3C protease (molar ratio target protein to protease 1: 5). Afterwards, the flowthrough containing the protein of interest was collected and the resin was washed with 1 CV of cleavage buffer. Excess protease was removed from the protein solution by incubating it for 15 min with 4 ml of Ni-NTA resin slurry (Thermo Scientific™) on a roller mixer. The cleaved protein was collected by transferring the suspension to an empty column and washing the resin with 1 CV of cleavage buffer. The protein was concentrated with a 30 kDa cut-off concentrator (Sartorius Stedim Biotech, 20 mL) for further experiments.

**RESULTS**

**Advantages of the Novel pL55 MBP Fusion Vector**

The expression of NupC is under the control of a strong promoter (T7) in pL54 and a weak one (ptac) in pL53. On the other hand, the linker between the MBP and HRV3C protease cleavage site is shorter in pL54 than in pL53 (Figure 1). The stronger promoter led to a higher level of expression (Figure 2A). Furthermore, as shown in Figure 3, the longer linker present in the protein expressed by pL53 led to better cleavage of the tag. Less HRV-3C protease is required to completely cleave protein expressed in pL53 than in pL54.

We therefore created a new MBP fusion vector, pL55, which includes a T7 promoter, a periplasmic targeting sequence (pelB), an octa histidine tag, MBP, and a human rhinovirus 3C protease cleavage site (HRV3C). The level of expression of NupC in a pL55 context is almost equivalent to level observed for pL54, and approximately double compared to pL53 (Figure 2A). This suggests that constructs with a T7 promoter (pL54 and pL55) could yield much more target membrane protein than constructs with a ptac promoter (pL53).

The efficient solubilisation of NupC produced by the pL55 construct by 5 different detergents shows that changing the length of the linkers or the strength of the promoter does not lead to the expression of the recombinant protein into inclusion bodies (Figure 2B). The pL55 vector, with a strong promoter and a long linker, thus combines the advantages of both pL53 and pL54 vectors. The expressed NupC was functional in all three different vectors according to a transport assay (Ma et al., 2015).

Additionally, we tested the cleavage efficiency of NupC expressed in pL53, pL54, and pL55 in the presence of different molar ratios of NupC:HRV3C after 16 h (Figure 3). The results show that the cleavage efficiency of NupC in pL53 was clearly higher than in pL54. The fusion NupC in pL55 can be cleaved efficiently following the same molar ratio NupC:HRV of 5:1 obtained from the test in pL53, as they possess equivalent length linker.

**Optimization of Purification Using MBP Fusion Protein**

A crucial parameter in membrane protein purification is the time required for their purification. The low stability of most membrane proteins inevitably leads to decreased protein yields due to denaturation, aggregation, and proteolysis during long purification protocols.

Our previous purification protocols for NupC required long binding times (usually overnight) of the resin with solubilized membrane proteins for complete adsorption, in order to maximize the final yield. In this new approach, we decided to investigate how the amount of unbound NupC
varied with incubation time. The Co-resin was incubated with solubilized NupC for 12 h. Samples were taken at 1, 2, 3, 4, and 12 h, centrifuged, and the amount of unbound target protein in the supernatant was determined via western blot and compared to the total initial amount. We found that more than 95% of the solubilized tagged protein was bound to the resin within 2 h, suggesting that the binding time could be significantly shortened from overnight to 2 h to avoid loss of activity during the long purification process (Figure 4A).

Conventional membrane protein production methods also generally require a long time for cleaving the MBP fusion protein off (overnight or even longer). To investigate how quickly cleavage occurs, we added the protease to the column-bound membrane protein (molar ratio NupC:HRV of 5:1) and compared the cleaved to uncleaved protein ratio at different incubation times by western blot (anti-histidine tag antibody) (Figure 4B). The results indicate that about 90% of the fusion protein was cleaved within 2 h, and that a longer incubation time did not significantly increase the cleavage yield. Therefore, the digestion time was reduced from 16 to 2 h in the optimized method. To determine the amount of protease required to achieve this, we examined the cleavage efficiency using different amounts of protease against recombinant NupC in the three different vectors (Figure 3). Our findings show that a 5:1 molar ratio of NupC:HRV protease was sufficient during the 16 h cleavage of NupC in the pL53 and pL55 vectors, which possess the same long linker. On the contrary, cleavage of NupC in pL54 with a short linker proved difficult, even using a large amount of protease (NupC:HRV of 1:1).

The purity of the protein was subsequently evaluated. After cleavage and concentration steps, the purified protein was loaded onto SDS-PAGE and stained with Coomassie Blue. Unexpectedly, three main bands were observed on the gel in addition to the NupC monomer (Figure 5). All four bands were identified as NupC by mass spectrometry analysis (data not shown), consistent with the fact that NupC can form higher oligomers and in particular trimers as seen in the 3D structure (Johnson et al., 2012). This suggests that purified NupC retains its native trimeric structure even in SDS-PAGE. Band 1 (less than 37 kDa) is presumably the NupC monomer. Bands 2 and 3 correspond to a dimer and trimer respectively, while band 4 (above 100 kDa) is some higher-order oligomeric structure.

This purification strategy has broad range applications for other membrane proteins. This is illustrated by the successful purification of the nucleoside transporter...
DISCUSSION

For a long time, the low yield of membrane proteins has presented a major obstacle for their structural and functional studies, especially for NTs. Many attempts have been made to overcome this problem using various expression strains, vectors and media for membrane proteins (Winstone et al., 2002; Drew et al., 2006; Öberg et al., 2011; Schlegel et al., 2012). The MBP protein, which was reported to increase the stability and solubility of membrane proteins (Gruswitz et al., 2005; Raran-Kurussi et al., 2015), was introduced into our nucleoside transporter expression vectors. Meanwhile, it has been reported that different promoters could change the expression level of target proteins, and a strong promoter, such as the T7 promoter in pL54, can facilitate the overexpression of the target protein (Berg et al., 2012; Phan et al., 2012; Hensel et al., 2013; Binder et al., 2014). Through combining a strong promoter for enhanced protein expression with MBP enhancing the protein stability as fusion partner we were able to construct a new expression vector (pL55), which resulted in significantly higher protein yields than our earlier vectors.

A limiting step in the purification of MBP fusion proteins has often been the rate of proteolytic cleavage of the MBP from the target proteins. It was reported that the incomplete digestion resulted from the presence of certain detergents during purification (Mohanty et al., 2003). Hu and colleagues...
speculated that detergent solubilisation of the hydrophobic cleft on the surface of MBP may form a binding site for the hydrophobic domain of the target membrane protein, which potentially results in a stable non-covalent complex following protein cleavage (Hu et al., 2011). In other words, the activity of the proteolytic enzyme can be dramatically reduced in the detergents used to solubilize membrane proteins (Vergis and Wiener, 2011). However, our results suggest that the rate of digestion is also dependent on the length of the linker between MBP and the target protein. We observed that digestion was more efficient when linkers were longer (pL55 and pL53, both 19 amino acids), as opposed to a shorter linker (pL54, 3 amino acids) (Figure 3). This is presumably because the cleavage site is more exposed and therefore more accessible to proteolytic enzymes when long linkers are employed. Indeed, smaller amounts of protease were needed to perform efficient digestion on the new His-MBP-NupC fusion expressed from our new vector, pL55, compared to pL54, a similar construct with a shorter linker. This means that the target protein can be purified much faster using the new vectors and methods (Figure 6): the time taken after ultracentrifugation is reduced from 37 to 6.5 h—almost a factor of six. Additionally, compared to the traditional purification protocol, the new method significantly reduces the consumption of reagents and lab consumables.

Furthermore, our new optimized method is particularly interesting for crystallization purposes. In traditional purification experiments, large volumes are used to elute the target protein efficiently. This implies that the purified protein is very diluted and a concentration step is required before downstream application. This in turn concentrates the detergent and has an impact on crystallization efficiency and crystal quality (Prince and Jia, 2013). Our optimized protocol describes how adding the protease directly onto the column-bound target protein reduces the volume of elution, hence yielding a more concentrated protein. Further protein concentration steps are therefore minimized, avoiding unnecessary collateral increase in detergent concentration, which is an important asset in crystallographic studies. Our new optimized strategy presents strong advantages over classical approaches in terms of time, cost, and quality of membrane protein purification for crystallographic studies.

**AUTHOR CONTRIBUTIONS**

AG, ZH, VP, YW, MB designed the experiments. ZH, VP, AL, MT, DS performed the experiments. The data were analyzed by ZH, MT, VP, AL, AG. The paper was written by ZH, MT, VP, YW, MB, and AG.

**FUNDING**

The authors are grateful to the financial support from the National key fundamental research project (973 project, 2014CB560709, to MB), National Science Foundation of China (31570128 to MB and 31270545 to YW), and the Royal Society Wolfson Research Merit Award, the Wellcome Trust (ref. 0193227/10/Z), BBSRC (BB/M021610/1) and the Academy of Finland (1286429) (all to AG). ZH...
was funded by an award from the China Scholarship Council.

ACKNOWLEDGMENTS

As colleagues and friends of Steve Baldwin, we dedicate this paper to him in memoriam.

REFERENCES

Alexandrov, A., Dutta, K., and Pascal, S. M. (2001). MBP fusion protein with a viral protease cleavage site: one-step cleavage/purification of insoluble proteins. Biotechniques 30, 1194–1198. doi: 10.1017/S1355839202024019

Almén, M. S., Nordström, K. J., Fredriksson, R., and Schiöth, H. B. (2009). Mapping the human membrane proteome: a majority of the human membrane proteins can be classified according to function and evolutionary origin. BMC Biol 7:50. doi: 10.1186/1741-7007-7-50

Andreeva, A., Howorth, D., Chothia, C., Kulesha, E., and Murzin, A. G. (2014). SCOP2 prototype: a new approach to protein structure mining. Nucleic Acids Res. 42, D310–D314. doi: 10.1093/nar/gkt1242

Anson, L. (2009). Membrane protein biophysics. Nature 459, 343. doi: 10.1038/459343a

Baldwin, S. A. (2000). Membrane Transport: A Practical Approach. New York, NY: Oxford University Press.

Bayley, H. (2009). Membrane-protein structure: piercing insights. Nature 459, 651–652. doi: 10.1038/459651a

Berg, L., Kucharova, V., Bakke, I., Valla, S., and Brautaset, T. (2012). Exploring the 3’-UTR DNA region as a target for optimizing recombinant gene expression from the strong and inducible Pm promoter in Escherichia coli. J. Biotechnol. 158, 224–230. doi: 10.1016/j.jbiotec.2011.07.012

Binder, D., Grünberger, A., Loeschcke, A., Probst, C., Bier, C., Pietruszka, J., et al. (2014). Light-responsive control of bacterial gene expression: precise triggering of the lac promoter activity using photocaged IPTG. Integr. Biol. (Camb.) 6, 755–765. doi: 10.1039/cib00027g

Bowie, J. U. (2005). Solving the membrane protein folding problem. Nature 438, 581–589. doi: 10.1038/nature04395

Carrier, E. J., Auchampach, J. A., and Hillard, C. J. (2006). Inhibition of an equilibrative nucleoside transporter by cannabidiol: a mechanism of cannabinoid immunosuppression. Proc. Natl. Acad. Sci. U.S.A. 103, 7895–7900. doi: 10.1073/pnas.0511232103

Dalkén, B., Jablonsky, R. A., Obiero, P., Benhar, I., and Wels, W. S. (2010). Maltose-binding protein enhances secretion of recombinant human granzyme B accompanied by in vivo processing of a precursor MBP fusion protein. PLoS ONE 5:e14404. doi: 10.1371/journal.pone.0014404

Drew, D., Lerch, M., Kunji, E., Slotboom, D. J., and De Gier, J. W. (2006). Optimization of membrane protein overexpression and purification using GFP fusions. Nat. Methods 3, 303–313. doi: 10.1038/nmeth0406-303

Drew, D., Newstead, S., Sonoda, Y., Kim, H., Von Heijne, G., and Iwata, S. (2008). GFP-based optimization scheme for the overexpression and purification of eukaryotic membrane proteins in Saccharomyces cerevisiae. Nat. Protoc. 3, 784–798. doi: 10.1038/nprot.2008.44

Drew, D., Slotboom, D. J., Friso, G., Reda, T., Genevaux, P., Rapp, M., et al. (2005). A scalable, GFP-based pipeline for membrane protein overexpression screening and purification. Protein Sci. 14, 2011–2017. doi: 10.1110/ps.0514662005

Gosch, C., Nagesh, K. M., Thill, J., Miosec, S., Plaschil, S., Milosec, M., et al. (2014). Isolation of dihydroflavonol 4-reductase cDNA clones from Angelonia x angustifolia and heterologous expression as GST fusion protein in Escherichia coli. PLoS ONE 9:e107755. doi: 10.1371/journal.pone.0107755

Gruuswitz, F., Frishman, M., Goldstein, B. M., and Wedekind, J. E. (2005). Coupling of MBP fusion protein cleavage with sparse matrix crystallization screens to overcome problematic protein solubility. Biotechniques 39, 478, 480. doi: 10.2144/000112033

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: http://journal.frontiersin.org/article/10.3389/fmolb.2016.00023

Si-Figure 1 | SDS-PAGE of the purified CNT from Anoxybacillus flavithermus (Af), Bacillus halodurans (Bh), Rhodothermus marinus (Rm) in DDM performed via the optimized procedure.
Rehan, S., and Jaakola, V. P. (2015). Expression, purification and functional characterization of human equilibrative nucleoside transporter subtype-1 (hENT1) protein from Sf9 insect cells. Protein Expr. Purif. 114, 99–107. doi: 10.1016/j.pep.2015.07.003

Sammons, J. D., and Gross, A. K. (2013). Biochemical analysis of a rhodopsin photoactivatable GFP fusion as a model of G-protein coupled receptor transport. Vision Res. 93, 43–48. doi: 10.1016/j.visres.2013.10.008

Satoh, K., Oti, T., Katoh, A., Ueta, Y., Morris, J. F., Sakamoto, T., et al. (2015). In vivo processing and release into the circulation of GFP fusion protein in arginine vasopressin enhanced GFP transgenic rats: response to osmotic stimulation. FEBS J. 282, 2488–2499. doi: 10.1111/febs.13291

Schlegel, S., Löfblom, J., Lee, C., Hjelm, A., Klepsch, M., Strous, M., et al. (2012). Optimizing membrane protein overexpression in the Escherichia coli strain Lemo21(DE3). J. Mol. Biol. 423, 648–659. doi: 10.1016/j.jmb.2012.07.019

Valdés, R., Elferich, J., Shinde, U., and Landfear, S. M. (2014). Identification of the intracellular gate for a member of the equilibrative nucleoside transporter (ENT) family. J. Biol. Chem. 289, 8799–8809. doi: 10.1074/jbc.M113.546960

Vergis, J. M., and Wiener, M. C. (2011). The variable detergent sensitivity of proteases that are utilized for recombinant protein affinity tag removal. Protein Expr. Purif. 78, 139–142. doi: 10.1016/j.pep.2011.04.011

Von Heijne, G. (2006). Membrane-protein topology. Nat. Rev. Mol. Cell Biol. 7, 909–918. doi: 10.1038/nrm2063

Winstone, T. L., Duncalf, K. A., and Turner, R. J. (2002). Optimization of expression and the purification by organic extraction of the integral membrane protein EmrE. Protein Expr. Purif. 26, 111–121. doi: 10.1016/S1046-5928(02)00525-9

Xiu, Y., Chen, B., He, Q. H., Qiu, Y. L., Liu, X., He, Z. Y., et al. (2014). New approach for development of sensitive and environmentally friendly immunoassay for mycotoxin fumonisin B(1) based on using peptide-MBP fusion protein as substitute for coating antigen. Anal. Chem. 86, 8433–8440. doi: 10.1021/ac502037w

Young, J. D., Yao, S. Y., Baldwin, J. M., Cass, C. E., and Baldwin, S. A. (2013). The human concentrative and equilibrative nucleoside transporter families, SLC28 and SLC29. Mol. Aspects Med. 34, 529–547. doi: 10.1016/j.mam.2012.05.007

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2016 Hao, Postis, Sharples, Wang, Bartlam and Goldman. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.